Pharmacovigilance Working Party (PhVWP)

The PhVWP recommended key elements of warnings for the product information of allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoin, meloxicam, piroxicam, tenoxicam, nevirapine, sulfadiazine, sulfadoxine, sulfafurazole, sulfamethoxazol and sulfasalazine regarding their rare risk of life-threatening Stevens-Johnson syndrome and toxic epidermal necrolysis for early detection of these adverse reactions and subsequent permanent discontinuation of the medicine to improve their outcomes.